miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222

Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis

(2010) Wen Gao et al.   BIOMEDICINE & PHARMACOTHERAPY

miR-212 Increases Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Sensitivity in Non–Small Cell Lung Cancer by Targeting the Antiapoptotic Protein PED

(2010) Mariarosaria Incoronato et al.   CANCER RESEARCH

Targeting the HGF/Met signalling pathway in cancer

(2010) Fabiola Cecchi et al.   EUROPEAN JOURNAL OF CANCER

miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation

(2009) Michela Garofalo et al.   CANCER CELL

MicroRNAs: Predictors and modifiers of chemo- and radiotherapy in different tumour types

(2009) Richard Hummel et al.   EUROPEAN JOURNAL OF CANCER

Causes and consequences of microRNA dysregulation in cancer

(2009) Carlo M. Croce   NATURE REVIEWS GENETICS

MicroRNA Expression Profiling in Human Ovarian Cancer: miR-214 Induces Cell Survival and Cisplatin Resistance by Targeting PTEN

(2008) H. Yang et al.   CANCER RESEARCH

Role of microRNAs in drug-resistant ovarian cancer cells

(2008) Antonio Sorrentino et al.   GYNECOLOGIC ONCOLOGY

MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer

(2008) M Garofalo et al.   ONCOGENE